Concordia Healthcare Corp. T.CXR.R

RE:RE:RE:The RBC report for April-21-2016

[Scruggstyle]

The decline in NA revenue in 2015 Q4 was largely a result of supply issues with the company’s contract manufacturer of Plaquenil, which limited CXR’s ability to ship both branded and authorized generic product in the quarter.  In addition, order timing impacted Lanoxin AG as large orders were booked in Q3 followed by a somewhat weaker Q4. TRx data has shown improved Lanoxin AG market share, and continued demand for Plaquenil AG in early 2016. Management indicated on the call that the supply issues that impacted Plaquenil availability in Q4 have been resolved in Q1/16 and that inventory levels and shipments should be back to normal in Q2/16.  (Excerpts from March 28, 2016 Scotia Report)

yycish1027 wrote: Thanks Craigbad for reading my post. I hope this provided some valuable discussion. 

Craigbad wrote: Starting to understand the short position a little better now. Those guys have the script info too. Their main drug is declining heavy and has more competition on the way. They buy Amco as a hail mary to washout declines and overleverage their balance sheet. Now its all on Amco to offset their declines, but Amco already jacked prices just before Concordia bought them so they have a some major headwinds for growth.